Quick Answer
MAIA Biotechnology, Inc. reported R&D Expense of $10.01 million for fiscal year 2024.
MAIA Biotechnology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $10.01M | -9.9% |
| 2023 | $11.11M | +24.4% |
| 2022 | $8.93M | +155.5% |
| 2021 | $3.50M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $3.20M | +37.8% | +19.9% |
| September 30, 2024 | $2.67M | +2.6% | +30.0% |
| June 30, 2024 | $2.05M | -21.0% | -11.6% |
| March 31, 2024 | $2.32M | +5.7% | -10.7% |
| September 30, 2023 | $2.60M | +10.9% | +0.0% |
| June 30, 2023 | $2.60M | +22.6% | +18.4% |
| March 31, 2023 | $2.20M | +5.7% | -6.3% |
| September 30, 2022 | $2.34M | +116.6% | +10.6% |
- MAIA Biotechnology, Inc. showed a decrease of -9.9% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2024 period, MAIA Biotechnology, Inc.’s r&d expense has grown by 186.2% (from $3.50 million to $10.01 million).
- The most recent figure is from MAIA Biotechnology, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 21, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: